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Background: Published data on the association between AURKA polymorphisms and breast cancer (BC) risk are
inconclusive. This meta-analysis was performed to derive a more precise estimation on the relationship between
AURKA polymorphisms (rs2273535 and rs1047972) and BC risk.
Methods: PubMed, Web of Knowledge and Embase were searched for relevant studies. Odds ratios (ORs) with 95%
confidence intervals (CIs) were used to estimate the strength of associations. The pooled odds ratios (ORs) with
95% confidence intervals (CIs) were performed for allele contrast genetic model, homozygous genetic model,
heterozygote genetic model, dominant model, and recessive model, respectively.
Results: A total of 13 studies (16,349 BC patients and 20,872 case-free controls) were involved in this meta-analysis.
Meta-analysis showed that there was significant association between rs2273535 and BC risk in three genetic models
in the overall population (A vs. T: OR = 1.08, 95% CI = 1.01–1.15, P = 0.02; AA vs. TT: OR = 1.36, 95% CI = 1.06-1.73,
P < 0.00001; AA vs. TT + TA: OR = 1.15, 95% CI = 1.01-1.31, P = 0.04). In the subgroup analysis by ethnicity, the effects
remained in Asians (allele contrast genetic model: OR = 1.12, 95% CI = 1.00-1.26, P = 0.04 and homozygote comparison:
OR = 1.22, 95% CI = 1.06-1.41, P = 0.007). However, no genetic models reached statistical association in Cauasians.
Rs1047972 polymorphism was associated with BC risk in the overall population based on homozygote comparison
(AA vs. GG: OR = 0.81, 95% CI = 0.66-0.99, P = 0.04). When stratified by ethnicity, rs1047972 polymorphism had a
decreased association with BC risk in Caucasians based on allele contrast genetic model, homozygote comparison,
the dominant model and the recessive model. However, there was no association in any genetic model in Asians.
Conclusions: This meta-analysis suggests that AURKA rs2273535 polymorphism has an increased risk with BC,
especially in Asians. However, rs1047972 polymorphism has a decreased BC risk in Caucasians. Further large scale
multicenter epidemiological studies are warranted to confirm this finding.
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Breast cancer (BC) is the most common cancer in women
and the incidence has increased in recent years worldwide
[1]. BC is also a complex disease with multiple epi-
demiological, genetic, and epigenetic factors contribut-
ing to disease etiology [2,3]. About 10% of all breast
cancers are associated with family history [4]. The clin-
ical features of human BC are characterized by a consid-
erable heterogeneity.
AURKA, also known as STK15/Aurora-A, belongs to
the Aurora family of cell cycle-regulating serine/threo-
nine kinase [5]. AURKA is localized at the centrosome
from the time of centrosome duplication to mitotic exit
and regulates centrosome function [6]. AURKA plays an
important role in mitotic centrosome separation, matur-
ation and spindle formation and stability [5-7]. Studies
have demonstrated that AURKA overexpression contrib-
utes to genetic instability and tumourigenesis by disrupt-
ing the proper assembly of the mitotic checkpoint
complex and occurs in a high proportion of ovarian, blad-
der, gastric and breast cancers [8-11].
Two nonsynonymous polymorphisms F31I (rs2273535)
and V57I (rs1047972) have been identified in the AURKA
gene. Both polymorphisms are located within two con-
served motifs in the N-terminal region of the AURKA
gene [12]. Several studies have reported the role of
AURKA polymorphisms in BC risk [13-25], but the results
are inconclusive. For example, Ruan et al. [13] reported
that the AA (Ile/Ile) genotype of rs2273535 was associated
with a significantly increased risk of breast cancer among
the Chinese Han population. However, Dai et al. Dai et al.
[23] that rs2273535 allele of the AURKA gene was not as-
sociated with breast cancer risk (OR 1.2, 95% CI 0.9–1.6).
There was also no apparent difference in allele frequency
or genotype of rs1047972 polymorphism (OR 0.8, 95% CI
0.4–1.6) [23]. Fletcher et al. [20] demonstrated that the
Ile/Ile homozygous genotype was not associated with an
increased BC risk in white women of British descent. Egan
et al. described an increased risk associated with a com-
pound genotype of the two polymorphisms, rs2273535
and rs1047972, with individuals homozygous for the 31I
and 57 V alleles having a nearly 2-fold increase in risk of
postmenopausal invasive BC [24].
Therefore, we carried out this meta-analysis on all eli-
gible case–control studies to derive a more precise estima-
tion of the associations between AURKA polymorphisms
(rs2273535 and rs1047972) with BC risk.
Materials and methods
Publication search
We searched the articles in PubMed, Web of Knowledge
and Embase to collect articles with case–control studies
related to the association of AURKA polymorphisms and
BC risk. The keywords were as follows: breast cancer/breast carcinoma, AURKA/Aurora-A/STK15, polymorph-
ism/genotype/SNP. All qualified studies were searched
until May 30, 2014. The eligible articles must be published
in English. Furthermore, reference lists of main reports
and review articles were also reviewed by a manual search
to identify additional relevant publications.
Selection and exclusion criteria
The following criteria were used to select studies for fur-
ther meta-analysis: (1) case–control studies; (2) the studies
evaluated the associations between AURKA polymor-
phisms and breast cancer risk; (3) all cases were diagnosed
by pathological examination; (4) the studies contained suffi-
cient genotype data for estimating an odds ratio (OR) with
95% confidence interval (CI); (5) genotype distributions of
controls passed Hardy-Weinberg equilibrium (HWE) test.
Accordingly, the following exclusion criteria were also
used: (1) the design of the experiments were not case–
control studies; (2) the source of cases and controls, and
other essential information were not provided; (3) the
genotype distribution of the control population was de-
parture from HWE; (4) reviews, meta-analysis and dupli-
cated publications.
Data extraction and synthesis
Information was carefully extracted from all eligible
studies independently by two authors according to the
inclusion criteria listed above. In case of disagreements,
another author was consulted to resolve the dispute, and
a final decision was made by the majority of the votes.
For each included study, the following information was
collected: first author, year of publication, country of ori-
gin, ethnicity, source of control, numble of cases and
controls, genotype methods, allele and genotype fre-
quencies and evidence of HWE in controls. Different
ethnicity descents were categorized as Caucasian, Asian,
and “mixed”. All the case and control groups were well
controlled. The non-cancer controls had no history of
gynecologic disease, and there was no present evidence
of any malignant disease.
Statistical analysis
The associations between AURKA polymorphisms and
BC risk were measured by odds ratio (OR) with 95%
confidence interval (CI). The significance of the pooled
OR was determined by the Z test. Statistical heterogeneity
among studies was assessed with the Q and I2 statistics.
If the P value of heterogeneity test was more than 0.1
(P ≥ 0.1), the pooled OR estimate of the study was calcu-
lated by the fixed-effects model. Otherwise, the random-
effects model was used [26]. The value of the I index is
used to assess the degree of heterogeneity (I2 < 25%: no
heterogeneity; 25% < I2 < 50%: moderate heterogeneity;
50% < I2 < 75%: high heterogeneity; I2 > 75%:extreme
105 potential relevant studies from PubMed, 
Web of Knowledge and Embase




21 potential relevant studies
Excluded after completely reading: 
2 no detailed genotyping data
2 not case-control studies
1 laboratory studies
3 systematic reviews
13 studies were finally identified in this 
meta-analysis
Figure 1 Flow chart of studies selection in this meta-analysis.
Table 1 Characteristics of the studies included in the meta-analysis
First author Year Country Ethnicity Design Genotyping medthod Number(case/control) SNP HWE
Ruan [13] 2011 China Asian PB TaqMan 1334/1568 rs2273535 0.76
Shi [14] 2011 Sweden Caucasian PB TaqMan 763/1516 rs2273535 0.23
MARIE-GENICA [15] 2010 German Caucasian PB MALDI-TOF 3137/5469 rs2273535 0.12
rs1047972 0.17
Couch [16] 2007 CIMBA Mixed PB TaqMan 3884/3303 rs2273535 NA
Tchatchou [17] 2007 German Caucasian PB TaqMan 727/819 rs2273535 0.60
Vidarsdottir [18] 2007 Iceland Caucasian NA PCR-RFLP 759/653 rs2273535 0.07
Cox [19] 2006 USA Caucasian NA TaqMan 1259/1742 rs2273535 0.31
rs1047972 0.70
Fletcher [20] 2006 UK Caucasian PB PCR-RFLP 507/875 rs2273535 0.13
Ewart-Toland [21] 2005 USA Mixed PB SnAPSHOT 898/448 rs2273535 0.81
Lo [22] 2005 China(Taiwan) Asian HB TaqMan 709/1972 rs2273535 0.23
rs1047972 0.80
Dai [23] 2004 China Asian PB TaqMan 1102/1188 rs2273535 0.07
rs1047972 0.68
Egan [24] 2004 USA Caucasian PB Sequencing 941/830 rs2273535 0.31
rs1047972 0.68
Sun [25] 2004 China Asian HB PCR-RFLP 520/520 rs2273535 0.11
HWE: Hardy–Weinberg equilibrium; PB: population based; HB: hospital-based; NA: not available; PCR: polymerase chain reaction; RFLP: restriction fragment length
polymorphism; MALDI–TOF MS: Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry; CIMBA: the Consortium of Investigators of Modifiers
of BRCA1/2 including 16 clinic and population-based research studies and multicenter consortia.
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http://www.cancerci.com/content/14/1/91high heterogeneity). Publication bias were evaluated by
the funnel plot and further assessed by the method of
Egger’s linear regression test. All statistical analyses
were carried out with the review manager version 5.1
(Revman; The Cochrane Collaboration, Oxford, UK).
Results
Characteristics of eligible studies
As shown in Figure 1, a total of 105 potential publica-
tions were extracted at first based on our selection
strategy. According to the inclusion criteria defined
above, 13 studies on AURKA polymorphisms and BC
risk were finally identified in this meta-analysis
[13-25]. These studies included 16,349 BC patients
and 20,872 cancer-free controls. The characteristics
of the included studies are listed in Tables 1. Among
the eligible thirteen studies, seven studies were per-
formed in Caucasians from Sweden, Germany,
Iceland, UK and USA [14,15,17-20,24]. Four were
based on Asian background and were carried out in
China [13,22,23,25]. Two studies were mixed ethni-
city descent [16,21]. All studies were case–control
studies. All BC cases were confirmed by histology or
pathology. Moreover, controls were mainly matchedTable 2 AURKA polymorphisms genotype distribution and all
First author Genotype (N)
Case Control
Total AA Aa aa Total AA
rs2273535 (T > A)
Ruan 2011 1334 599 568 167 1568 716
Shi 2011 763 27 222 514 1516 71
MARIE-GENICA 2010 3076 1873 1096 107 5466 3290
Couch 2007 3884 3696 188 3303 3128
Tchatchou 2007 727 37 257 433 819 47
Vidarsdottir 2007 759 429 288 42 653 401
Cox 2006 1241 774 401 66 1711 1075
Fletcher 2006 507 335 154 18 875 547
Ewart-Toland 2005 898 533 303 62 448 279
Lo 2005 707 71 288 348 1969 196
Dai 2004 1102 121 491 490 1186 149
Egan 2004 940 559 331 50 830 516
Sun 2004 520 50 214 256 520 66
rs1047972 (G > A)
MARIE-GENICA 2010 3139 2220 850 69 5469 3737
Cox 2006 1240 870 342 28 1724 1215
Lo 2005 704 543 146 15 1950 1506
Dai 2004 1102 805 281 16 1188 908
Egan 2004 905 637 245 23 788 542
A represents the major allele, a represents the minor allele. MAF: minor allele frequon age, of which nine were population-based and two
were hospital-based studies.
Meta-analysis results
As shown in Table 2, the frequencies of the minor allele
in BC patients varied widely across the eligible studies,
ranging from 0.19 to 0.82 (rs2273535), 0.13 to 0.16
(rs1047972). The average frequencies of the minor al-
lele in the two polymorphisms were 0.39 and 0.15,
respectively.
The main results of this meta-analysis were listed in
Table 3. There were 13 studies with 16,286 BC patients
and 20,689 case-free controls for AURKA rs2273535
polymorphism. As show in Table 3 and Figure 2, there
was significant association between rs2273535 and BC
risk in three genetic models in the overall population (A
vs. T: OR = 1.08, 95% CI = 1.01–1.15, P =0.02; AA vs.
TT: OR = 1.36, 95% CI = 1.06-1.73, P < 0.00001; AA vs.
TT + TA: OR = 1.15, 95% CI = 1.01-1.31, P = 0.04), while
there was no significant association in heterozygote com-
parison and the dominant model (TA vs. TT: OR =1.02,
95% CI = 0.96-1.08, P = 0.52; TA +AA vs. TT: OR = 1.04,
95% CI = 0.98-1.09, P = 0.20). In the subgroup analysis by
ethnicity, the effects remained in Asians (allele contrastele frequency in cases and controls
Allele frequency (N) MAF
(Case/Control)Case Control
Aa aa A a A a
691 161 1766 902 2123 1013 0.34/0.32
478 967 276 1250 620 2412 0.82/0.80
1927 249 4842 1310 8507 2425 0.21/0.22
175 - - - - -
287 485 331 1123 381 1257 0.77/0.77
231 21 1146 372 1033 273 0.25/0.21
571 65 1949 533 2721 701 0.22/0.21
280 48 824 190 1374 376 0.19/0.22
148 21 1369 427 706 190 0.24/0.21
887 886 430 984 1279 2659 0.70/0.68
503 534 733 1471 801 1571 0.67/0.66
283 31 1449 431 1315 345 0.23/0.21
262 192 314 726 394 646 0.70/0.62
1561 171 5290 988 9035 1903 0.16/0.17
462 47 2082 398 2892 556 0.16/0.16
414 30 1232 176 3426 474 0.13/0.12
263 17 1891 313 2079 297 0.14/0.13
225 21 1519 291 1309 267 0.16/0.17
encies.
Table 3 Meta-analysis results
Comparisons OR 95%CI P value Heterogeneity Effects
modelI2 P value
a vs A
rs2273535 1.08 1.01–1.15 0.02 62% 0.002 R
Caucasian 1.05 0.96–1.14 0.31 63% 0.01 R
Asian 1.12 1.00–1.26 0.04 66% 0.03 R
rs1047972 0.98 0.89–1.08 0.75 55% 0.06 R
Caucasian 0.92 0.86–0.98 0.01 0% 0.38 F
Asian 1.10 0.97–1.25 0.14 0% 0.37 F
aa vs AA
rs2273535 1.36 1.06–1.73 <0.00001 82% <0.00001 R
Caucasian 1.32 0.85–2.03 0.21 88% <0.00001 R
Asian 1.22 1.06–1.41 0.007 24% 0.27 F
rs1047972 0.81 0.66–0.99 0.04 22% 0.28 F
Caucasian 0.74 0.59–0.93 0.009 0% 0.56 F
Asian 1.22 0.77–1.95 0.40 0% 0.57 F
Aa vs AA
rs2273535 1.02 0.96–1.08 0.52 0% 0.83 F
Caucasian 1.02 0.95–1.09 0.64 0% 0.67 F
Asian 1.02 0.90–1.14 0.80 0% 0.49 F
rs1047972 0.98 0.91–1.05 0.51 41% 0.14 F
Caucasian 0.94 0.87–1.02 0.15 0% 0.46 F
Asian 1.10 0.95–1.26 0.20 51% 0.15 F
Aa + aa vs AA
rs2273535 1.04 0.98–1.09 0.20 12% 0.33 F
Caucasian 1.02 0.95–1.08 0.61 31% 0.19 F
Asian 1.07 0.96–1.20 0.21 0% 0.48 F
rs1047972 0.99 0.89–1.10 0.84 51% 0.09 R
Caucasian 0.92 0.86–1.00 0.04 0% 0.40 F
Asian 1.10 0.96–1.27 0.16 33% 0.22 F
aa vs AA + Aa
rs2273535 1.15 1.01–1.31 0.04 69% 0.0001 R
Caucasian 1.13 0.92–1.38 0.24 66% 0.007 R
Asian 1.23 1.10–1.50 0.05 76% 0.006 R
rs1047972 0.82 0.67–1.00 0.05 14% 0.33 F
Caucasian 0.75 0.60–0.94 0.01 0% 0.60 F
Asian 1.20 0.75–1.91 0.44 0% 0.50 F
A: represents the major allele, a: represents the minor allele, F: fixed effects
model, R: random effects model.
Dai et al. Cancer Cell International 2014, 14:91 Page 5 of 8
http://www.cancerci.com/content/14/1/91genetic model: OR = 1.12, 95% CI = 1.00-1.26, P = 0.04 and
homozygote comparison: OR = 1.22, 95% CI = 1.06-1.41,
P = 0.007). However, no genetic models reached statistical
association in Cauasians (Table 3).
5 studies with 7,090 cases and 11,119 controls were used
to assess the relationship between rs1047972 polymorph-
ism and BC risk. As shown in Table 3 and Figure 3,rs1047972 polymorphism was associated with BC risk in
the overall population based on homozygote comparison
(AA vs. GG: OR = 0.81, 95% CI = 0.66-0.99, P = 0.04).
There was no association in these four genetic models (al-
lele contrast genetic model: OR = 0.98, 95%CI = 0.89-1.08,
P = 0.75; heterozygote comparison: OR =0.98, 95% CI =
0.91-1.05, P = 0.51; dominant model: OR =0.99, 95% CI =
0.89-1.10, P = 0.84); recessive model (OR = 0.82, 95% CI =
0.67-1.00, P = 0.05). When stratified by ethnicity,
rs1047972 polymorphism had a decreased association
with BC risk in Caucasians based on allele contrast gen-
etic model: OR = 0.92, 95%CI = 0.86-0.98, P = 0.01; homo-
zygote comparison: OR = 0.74, 95% CI = 0.59-0.93, P =
0.009; dominant model: OR =0.92, 95% CI = 0.86-1.00,
P = 0.04); recessive model (OR = 0.75, 95% CI = 0.60-0.94,
P = 0.01). However, there was no association in any gen-
etic model in Asians.
Publication bias
Begg's funnel plot and Egger's test were performed to as-
sess the publication bias. As shown in Figure 4, the funnel
plots did not reveal any obvious asymmetry in all geno-
types in overall population, and the results of Egger’s test
revealed no publication bias (P > 0.05).
Discussion
AURKA is associated with centrosomes, being localized
at the centrosome just prior to the onset of mitosis and
for the duration of mitosis. Overexpression of AURKA
leads to centrosome amplification and cellular trans-
formation [27]. This threonine kinase belongs to a family
of mitotic kinases that maintain chromosomal stability
through phosphorylation. Thus, any severe defects in
AURKA, such as mutations, would lead to drastic gen-
omic instability and induce apoptosis through cell cycle
checkpoint surveillance [11,28]. Consequently, the cell
harboring a defective AURKA may lead to cancer [11].
Epidemiological studies have been performed to assess
the association of AURKA polymorphisms (rs2273535
and rs1047972) with BC risk. However, the results are
conflicting. Thus, we conducted a comprehensive meta-
analysis involving published data, to assess the strength
of association between the two polymorphisms and BC
risk. In this present meta-analysis, 13 studies with 16,286
BC patients and 20,689 case-free controls concerning the
rs2273535 polymorphism, 5 studies with 7,090 cases and
11,119 controls concerning the rs1047972 polymorphism,
were included, respectively. And we explored the associ-
ation between the two potentially functional polymor-
phisms of AURKA and BC risk.
In the overall population, we found that rs2273535
polymorphism had an increased association with BC risk
in three genetic models (allele contrast genetic model:
OR = 1.08, 95% CI = 1.01–1.15, P =0.02; homozygote
Figure 2 Forest plots of AURKA rs2273535 polymorphism and BC risk (AA vs TT + TA). The squares and horizontal lines correspond to the
study specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and
95% CI.
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recessive model: OR = 1.15, 95% CI = 1.01-1.31, P = 0.04).
However, rs1047972 polymorphism had a decreased as-
sociation with BC risk based on homozygote comparison
(OR = 0.81, 95% CI = 0.66-0.99, P = 0.04).
In the stratified analysis based on ethnicity, rs2273535
polymorphism had increased BC risk in Asians based on
allele contrast genetic model, homozygote comparison,
and the recessive model. However, no genetic models
reached statistical association in Cauasians. For rs1047972
polymorphism, there was no significant association in
Asians. Rs1047972 had a decreased BC risk in Caucasians
based on allele contrast genetic model, homozygote com-
parison, the dominant model, and the recessive model.
In a previous meta-analysis by Qin et al. [29], they failed
to find any significant association between rs1047972
polymorphism and BC risk. It is worth mentioning, the re-
sults of the present study are not in accordance with Qin’s
analysis. This discrepancy may result from differentsample size and ethnic groups. There were only seven
studies including 5966 cases and 7609 controls in Qin’s
meta-analysis [29], while 13 studies (16,349 BC patients
and 20,872 case-free controls) were involved in our
meta-analysis.
There are some limitations in this meta-analysis. Firstly,
this meta-analysis was based on pooled data. We could
not assess the risk of cancer according to stratification of
age, smoking, alcohol consumption, environment factors,
and other risk factors. Secondly, no individual data such
as pathological type, histologic grade, and other clin-
icopathological index was available. Thus, we could not
assess the clinicopathological significance of the poly-
morphisms in BC. Thirdly, there were only published
studies including in the meta-analysis. It is possible that
some related unpublished studies that might meet the
inclusion criteria were missed. Finally, the included
studies were mainly based on Caucasian background.
There were only four studies based on Asian background
Figure 3 Forest plots of AURKA rs1047972 polymorphism and BC risk (AA vs GG). The squares and horizontal lines correspond to the study
specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.
Figure 4 Funnel plot assessing evidence of publication bias
from the eligible studies. A: F31I (rs2273535); B: V57I (rs1047972).
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scale multicenter studies based on Asian or African are
warranted to further validate on AURKA polymorphisms
and BC risk.
Conclusion
In summary, this meta-analysis suggests that AURKA
rs2273535 polymorphism has an increased risk with BC,
especially in Asians. However, rs1047972 polymorphism
has a decreased BC risk in Caucasians. Our results indi-
cate that AURKA rs2273535 is a candidate gene poly-
morphism, and rs1047972 polymorphism is a protective
factor for BC cancer risk. We conclude that the two
polymorphisms may be potential biomarkers in diagnosis
and prediction of BC risk. Further large scale epidemio-
logical studies are needed to confirm these findings.
Competing interest
The authors declare that they have no competing interests.
Authors’ contributions
DZJ and LXX designed the research. DZJ, WXJ, KHF and LS performed the
experiments throughout this research. ZY, RHT, MWL and WXJ participated in
its design and coordination. LS and WM analyzed the data; DZJ, KHF and
SYP contributed to the writing of the manuscript. Co-first authors: DZJ, KHF
and WXJ. All authors have read and approved the final manuscript.
Acknowledgments
This study was supported by the International Cooperative Project of Shaanxi
province, People’s Republic of China (No. 2013KW-32-01); China Postdoctoral
Science Foundation; the Fundamental Research Funds for the Central
Universities, China and Specialized Research Fund of the Second Affiliated
Hospital of Xi'an Jiaotong University, China [RC (GG) 201203].
Dai et al. Cancer Cell International 2014, 14:91 Page 8 of 8
http://www.cancerci.com/content/14/1/91Author details
1Department of Oncology, the Second Affiliated Hospital of Xi’an Jiaotong
University, Xi’an 710004, China. 2Center for Translational Medicine, Frontier
Institute of Science and Technology (FIST), Xi’an Jiaotong University, Xi’an
710049, China.
Received: 25 June 2014 Accepted: 1 September 2014
Published: 5 September 2014References
1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin
2013, 63:11–30.
2. Lo PK, Sukumar S: Epigenomics and breast cancer. Pharmacogenomics
2008, 9:1879–1902.
3. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M,
Pukkala E, Skytthe A, Hemminki K: Environmental and heritable factors in
the causation of cancer analyses of cohorts of twins from Sweden,
Denmark, and Finland. N Engl J Med 2000, 343:78–85.
4. Hemminki K, Granstrom C, Czene K: Attributable risks for familial breast
cancer by proband status and morphology: a nationwide epidemiologic
study from Sweden. Int. J. Cancer 2002, 100:214–219.
5. Carvajal RD, Tse A, Schwartz GK: Aurora kinases: new targets for cancer
therapy. Clin Cancer Res 2006, 12:6869–6875.
6. Castro A, Arlot-Bonnemains Y, Vigneron S, Labbé JC, Prigent C, Lorca T:
APC/Fizzy-Related targets Aurora-A kinase for proteolysis. EMBO Rep
2002, 3:457–462.
7. Fu J, Bian M, Jiang Q, Zhang C: Roles of Aurora kinases in mitosis and
tumorigenesis. Mol Cancer Res 2007, 5:1–10.
8. Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, Fiorica JV,
Nicosia SV, Cheng JQ: Activation and overexpression of centrosome
kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 2003,
9:1420–1426.
9. Fraizer GC, Diaz MF, Lee IL, Grossman HB, Sen S: Aurora-A/STK15/ BTAK
enhances chromosomal instability in bladder cancer cells. Int J Oncol
2004, 25:1631–1639.
10. Kamada K, Yamada Y, Hirao T, Fujimoto H, Takahama Y, Ueno M, Takayama
T, Naito A, Hirao S, Nakajima Y: Amplification/overexpression of Aurora-A
in human gastric carcinoma: potential role in differentiated type gastric
carcinogenesis. Oncol Rep 2004, 12:593–599.
11. Goepfert TM, Adigun YE, Zhong L, Gay J, Medina D, Brinkley WR:
Centrosome amplification and overexpression of aurora A are early
events in rat mammary carcinogenesis. Cancer Res 2002, 62:4115–4122.
12. Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J, Chan F,
MacCarthy-Morrogh L, Ponder BA, Nagase H, Burn J, Ball S, Almeida M,
Linardopoulos S, Balmain A: Identification of Stk6/STK15 as a candidate
low-penetrance tumor susceptibility gene in mouse and human.
Nat Genet 2003, 34:403–412.
13. Ruan Y, Song AP, Wang H, Xie YT, Han JY, Sajdik C, Tian XX, Fang WG:
Genetic polymorphisms in AURKA and BRCA1 are associated with
breast cancer susceptibility in a Chinese Han population. J Pathol 2011,
225:535–543.
14. Shi H, Bevier M, Johansson R, Grzybowska E, Chen B, Eyfjörd JE, Hamann U,
Manjer J, Enquist K, Henriksson R, Carlson J, Brandt A, Lascorz J, Butkiewicz
D, Pamula-Pilat J, Tecza K, Herms S, Hoffmann P, Hemminki K, Lenner P,
Försti A: Single nucleotide polymorphisms in the 20q13 amplicon genes
in relation to breast cancer risk and clinical outcome. Breast Cancer Res
Treat 2011, 130:905–916.
15. MARIE-GENICA Consortium: Polymorphisms in the BRCA1 and ABCB1
genes modulate menopausal hormone therapy associated breast cancer
risk in postmenopausal women. Breast Cancer Res Treat 2010, 120:727–736.
16. Couch FJ, Sinilnikova O, Vierkant RA, Pankratz VS, Fredericksen ZS, Stoppa-
Lyonnet D, Coupier I, Hughes D, Hardouin A, Berthet P, Peock S, Cook M,
Baynes C, Hodgson S, Morrison PJ, Porteous ME, Jakubowska A, Lubinski J,
Gronwald J, Spurdle AB, kConFab, Schmutzler R, Versmold B, Engel C, Meindl
A, Sutter C, Horst J, Schaefer D, Offit K, Kirchhoff T, et al: AURKA F31I
polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation
carriers: a consortium of investigators of modifiers of BRCA1/2 study.
Cancer Epidemiol Biomarkers Prev 2007, 16:1416–1421.
17. Tchatchou S, Wirtenberger M, Hemminki K, Sutter C, Meindl A,
Wappenschmidt B, Kiechle M, Bugert P, Schmutzler RK, Bartram CR,Burwinkel B: Aurora kinases A and B and familial breast cancer risk.
Cancer Lett 2007, 247:266–272.
18. Vidarsdottir L, Bodvarsdottir SK, Hilmarsdottir H, Tryggvadottir L, Eyfjord JE:
Breast cancer risk associated with AURKA 91 T > A polymorphism in
relation to BRCA mutations. Cancer Lett 2007, 250:206–212.
19. Cox DG, Hankinson SE, Hunter DJ: Polymorphisms of the AURKA (STK15/
Aurora Kinase) gene and breast cancer risk (United States). Cancer Causes
Control 2006, 17:81–83.
20. Fletcher O, Johnson N, Palles C, dos Santos Silva I, McCormack V, Whittaker
J, Ashworth A, Peto J: Inconsistent associ-ation between the STK15 F31I
genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2006,
98:1014–1018.
21. Ewart-Toland A, Dai Q, Gao YT, Nagase H, Dunlop MG, Farrington SM,
Barnetson RA, Anton-Culver H, Peel D, Ziogas A, Lin D, Miao X, Sun T,
Ostrander EA, Stanford JL, Langlois M, Chan JM, Yuan J, Harris CC, Bowman
ED, Clayman GL, Lippman SM, Lee JJ, Zheng W, Balmain A: Aurora-A/STK15
T91A is a general low penetrance cancer susceptibility gene: a
meta-analysis of multiple cancer types. Carcinogenesis 2005, 26:1368–1373.
22. Lo YL, Yu JC, Chen ST, Yang HC, Fann CS, Mau YC, Shen CY: Breast cancer
risk associated with genotypic polymor-phism of the mitosis-regulating
gene Aurora-A/STK15/BTAK. Int J Cancer 2005, 115:276–283.
23. Dai Q, Cai QY, Shu XO, Ewart-Toland A, Wen WQ, Balmain A, Gao YT,
Zheng W: Synergistic effects of STK15 gene polymorphisms and
endogenous estrogen exposure in the risk of breast cancer.
Cancer Epidemiol Biomarkers Prev 2004, 13:2065–2070.
24. Egan KM, Newcomb PA, Ambrosone CB, Trentham-Dietz A, Titus-Ernstoff L,
Hampton JM, Kimura MT, Nagase H: STK15 polymorphism and breast
cancer risk in a population-based study. Carcinogenesis 2004,
25:2149–2153.
25. Sun T, Miao X, Wang J, Tan W, Zhou Y, Yu C, Lin D: Functional Phe31Ile
polymorphism in Aurora A and risk of breast carcinoma. Carcinogenesis
2004, 25:2225–2230.
26. Dai ZJ, Wang XJ, Zhao Y, Ma XB, Kang HF, Min WL, Lin S, Yang PT,
Liu XX: Effects of interleukin-10 polymorphisms (rs1800896, rs1800871
and rs1800872) on breast cancer risk: evidence from an update
meta-analysis. Genet Test Mol Biomarkers 2014, 18:439–445.
27. Lukasiewicz KB, Lingle WL: Aurora A, centrosome structure, and the
centrosome cycle. Environ Mol Mutagen 2009, 50:602–619.
28. Marumoto T, Zhang D, Saya H: Aurora-A - a guardian of poles. Nat Rev
Cancer 2005, 5:42–50.
29. Qin K, Wu C, Wu X: Two nonsynonymous polymorphisms (F31I and V57I)
of the STK15 gene and breast cancer risk: a meta-analysis based on
5966 cases and 7609 controls. J Int Med Res 2013, 41:956–963.
doi:10.1186/s12935-014-0091-y
Cite this article as: Dai et al.: Association between genetic
polymorphisms in AURKA (rs2273535 and rs1047972) and breast cancer
risk: a meta-analysis involving 37,221 subjects. Cancer Cell International
2014 14:91.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
